TherapeuticsMD Inc (NASDAQ:TXMD) dropped 5.5% on Tuesday after an insider sold shares in the company. The company traded as low as $4.83 and last traded at $4.85. Approximately 2,418,824 shares were traded during mid-day trading, a decline of 7% from the average daily volume of 2,611,753 shares. The stock had previously closed at $5.13.
Specifically, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $6.24, for a total value of $1,148,160.00. Following the completion of the sale, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at $115,349,888.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John C.K. Iv Milligan sold 250,000 shares of the firm’s stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $6.10, for a total value of $1,525,000.00. Following the completion of the sale, the insider now directly owns 1,597,419 shares of the company’s stock, valued at approximately $9,744,255.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,722,728 shares of company stock valued at $20,590,153. 22.85% of the stock is currently owned by insiders.
TXMD has been the subject of several recent analyst reports. Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Friday, August 10th. Oppenheimer set a $14.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, August 13th. JPMorgan Chase & Co. set a $11.00 price objective on TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, August 17th. Finally, BidaskClub raised TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 29th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $13.45.
The stock has a market cap of $1.20 billion, a PE ratio of -13.11 and a beta of 1.35. The company has a quick ratio of 7.15, a current ratio of 7.23 and a debt-to-equity ratio of 0.55.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Wednesday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $4.43 million. TherapeuticsMD had a negative return on equity of 102.15% and a negative net margin of 757.59%. The business’s revenue for the quarter was down 21.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.07) earnings per share. As a group, equities research analysts anticipate that TherapeuticsMD Inc will post -0.58 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in TherapeuticsMD by 9.8% during the third quarter. Vanguard Group Inc. now owns 12,894,027 shares of the company’s stock valued at $84,585,000 after purchasing an additional 1,153,716 shares during the last quarter. B. Riley Wealth Management Inc. acquired a new stake in TherapeuticsMD during the third quarter valued at $102,000. Teachers Advisors LLC boosted its position in TherapeuticsMD by 13.3% during the third quarter. Teachers Advisors LLC now owns 353,895 shares of the company’s stock valued at $2,322,000 after purchasing an additional 41,607 shares during the last quarter. MetLife Investment Advisors LLC boosted its position in TherapeuticsMD by 54.0% during the third quarter. MetLife Investment Advisors LLC now owns 121,657 shares of the company’s stock valued at $798,000 after purchasing an additional 42,669 shares during the last quarter. Finally, Nexthera Capital LP acquired a new stake in TherapeuticsMD during the third quarter valued at $8,575,000. 72.66% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD (TXMD) Trading Down 5.5% Following Insider Selling” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/12/06/therapeuticsmd-txmd-trading-down-5-5-following-insider-selling.html.
TherapeuticsMD Company Profile (NASDAQ:TXMD)
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Read More: SEC Filing
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.